Sunesis Pharmaceuticals, Inc. (SNSS)
(Delayed Data from NSDQ)
$1.37 USD
+0.05 (3.79%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.37 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.37 USD
+0.05 (3.79%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.37 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Implied Volatility Surging for Sunesis Pharmaceuticals (SNSS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.
Sunesis Pharmaceuticals (SNSS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sunesis (SNSS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for Sunesis Pharmaceuticals (SNSS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.
Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
Is Sunesis Pharmaceuticals (SNSS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS).
Sunesis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Sunesis Pharmaceuticals' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.
Options Traders Expect Huge Moves in Sunesis (SNSS) Stock
by Zacks Equity Research
Investors need to pay close attention to Sunesis (SNSS) stock based on the movements in the options market lately.
What's in the Cards for Sunesis (SNSS) This Earnings Season?
by Zacks Equity Research
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
5 Cancer-Fighting Stocks to Boost Portfolio Gains
by Swarup Gupta
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
Will Sunesis Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.
Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up
by Zacks Equity Research
Puma Biotech (PBYI) betters loss estimates in Q4 and also rides high on revenue beat. Nerlynx impresses with strong sequential and year-over-year growth.
Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock
by Zacks Equity Research
Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.
Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
by Zacks Equity Research
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
5 Top-Ranked Rising P/E Stocks to Lure Investors
by Sanghamitra Saha
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
5 Biotech Stocks Under $10 Worthy of Investors' Attention
by Indrajit Bandyopadhyay
Small biotech stocks are good bets with lower market cap as well as share price.
Are Options Traders Betting on a Big Move in Sunesis Pharmaceuticals (SNSS) Stock?
by Zacks Equity Research
Investors in Sunesis Pharmaceuticals (SNSS) need to pay close attention to the stock based on moves in the options market lately.
Zacks.com featured highlights include MINDBODY, TearLab, Sunesis Pharmaceuticals, Children's Place, Franklin Electric
by Zacks Equity Research
Zacks.com featured highlights include MINDBODY, TearLab, Sunesis Pharmaceuticals, Children's Place, Franklin Electric
Step Beyond Bargain Hunting: 5 Stocks With Rising P/E
by Zacks Equity Research
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4
by Zacks Equity Research
Endocyte, Inc. (ECYT) reported a fourth-quarter 2016 loss of 26 cents per share, wider than both the Zacks Consensus Estimate of a loss of 25 cents and the year-ago loss of 23 cents.
Alexion's sBLA for Soliris Receives FDA Acknowledgement
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA, on Mar 9, has accepted the supplemental Biologics License Application (sBLA) to expand the indication for Soliris